.gif | width = 166 | CAS_number = 63121-00-6 | ATC_prefix = L01 | ATC_suffix = XA03 | ATC_supplemental = | PubChem = 77994 | DrugBank = APRD00186 | chemical_formula = C₈H₁₂N₂O₄Pt | molecular_weight = 395.27 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = Intravenous | excretion = Renal }} Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility.

Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

Mechanism of action and efficacy

---

In vivo studies showed Oxaliplatin has anti-tumor activity against colon carcinoma through its (non-targeted) cytotoxic effects. Median patient survival is approximately 5 months greater compared to the previous standard treatment.

Side-effects

---

Side-effects of oxaliplatin treatment can potentially include:

• Neuropathy, (both an acute, reversible sensitivity to cold and numbness in the hands and feet and a chronic, possibly irreversible foot/leg, hand/arm numbness, often with deficits in proprioception)
• Fatigue
• Nausea,vomiting, and/or diarrhea
• Neutropenia
• Hearing loss

In addition, some patients may experience an allergic reaction to platinum-containing drugs.

References

---

• Graham J, Mushin M, Kirkpatrick P.: Oxaliplatin. Nat Rev Drug Discov 2004;3:11-2. PMID 14756144. Fulltext.
• Eloxatin web site

Chemotherapeutic agents | Platinum compounds | Coordination compounds

Oxaliplatin | Oxaliplatine | オキサリプラチン